Education
About Us
Working with TipRanks
Follow Us
Heidelberg Pharma AG (DE:HPHA)
:HPHA
HPHA Stock Chart & Stats
€2.98
€0.02(0.83%)
At close: 4:00 PM EST
€2.98
€0.02(0.83%)
Day’s Range― - ―
52-Week Range€2.11 - €5.36
Previous CloseN/A
Volume3.96K
Average Volume (3M)9.20K
Market Cap
€137.08M
Enterprise Value€161.94M
Total Cash (Recent Filing)€33.25M
Total Debt (Recent Filing)€122.23K
Price to Earnings (P/E)―
Beta0.95
Next Earnings
Jul 10, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding46,784,317
10 Day Avg. Volume7,374
30 Day Avg. Volume9,196
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
HPHA FAQ
What was Heidelberg Pharma AG’s price range in the past 12 months?
Heidelberg Pharma AG lowest stock price was €2.11 and its highest was €5.36 in the past 12 months.
What is Heidelberg Pharma AG’s market cap?
Heidelberg Pharma AG’s market cap is €137.08M.
When is Heidelberg Pharma AG’s upcoming earnings report date?
Heidelberg Pharma AG’s upcoming earnings report date is Jul 10, 2025 which is 107 days ago.
How were Heidelberg Pharma AG’s earnings last quarter?
Heidelberg Pharma AG released its earnings results on Mar 21, 2025. The company reported -€0.127 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.127.
Is Heidelberg Pharma AG overvalued?
According to Wall Street analysts Heidelberg Pharma AG’s price is currently Overvalued.
Does Heidelberg Pharma AG pay dividends?
Heidelberg Pharma AG does not currently pay dividends.
What is Heidelberg Pharma AG’s EPS estimate?
Heidelberg Pharma AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Heidelberg Pharma AG have?
Heidelberg Pharma AG has 46,784,317 shares outstanding.
What happened to Heidelberg Pharma AG’s price movement after its last earnings report?
Heidelberg Pharma AG reported an EPS of -€0.127 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.247%.
Which hedge fund is a major shareholder of Heidelberg Pharma AG?
Currently, no hedge funds are holding shares in DE:HPHA
Heidelberg Pharma AG Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
13.85%
12-Months-Change
Fundamentals
Return on Equity
-112.95%
Trailing 12-Months
Asset Growth
-17.82%
Trailing 12-Months
Company Description
Heidelberg Pharma AG
Heidelberg Pharma AG (HPHA) is a biopharmaceutical company based in Germany specializing in the development of innovative therapeutics for the treatment of cancer. The company focuses on its proprietary ATAC technology (Antibody Targeted Amanitin Conjugates), which enables the targeted delivery of potent therapeutic agents directly to cancer cells. This approach is designed to minimize damage to healthy tissue while maximizing the efficacy of the treatment. HPHA operates primarily in the biopharmaceutical sector, with a strong emphasis on research and development of novel therapies that leverage its unique technology platform.
Technical Analysis
4SC AG
―
Biotest
―
B.R.A.I.N. Biotechnology Research and Information Network
―
Medios AG
―
Formycon AG
―